Semaglutide cuts heavy drinking days 41%
- Researchers at Copenhagen University Hospital and NIH reported that weekly semaglutide beat placebo in a 26-week alcohol-use trial for 108 adults with obesity. - Heavy drinking days fell 41.1% with semaglutide, an estimated 13.7 percentage points more than placebo, alongside lower craving and better alcohol biomarkers. - It matters because alcohol-use medications are limited and underused, and GLP-1 drugs now look like a plausible new treatment path.
Alcohol use disorder is one of those conditions where the need is obvious but the drug toolbox is still thin. A lot of people never get treated, and the few approved medications are not exactly household names. That is why this semaglutide result lands so hard. In a 26-week randomized trial published in *The Lancet* on April 30, researchers showed that weekly semaglutide cut heavy drinking days meaningfully more than placebo in treatment-seeking adults who had both alcohol use disorder and obesity. ### What actually changed? This was not another database study or a survey of people already taking Ozempic or Wegovy. It was a double-blind, placebo-controlled trial — the kind of evidence people have been waiting for. The team enrolled 108 adults in Denmark, gave everyone cognitive behavioral therapy, and then randomized them to weekly semaglutide or placebo for 26 weeks. ### How big was the effect? The headline number is the reduction in heavy drinking days. Semaglutide patients saw a 41.1% drop, which worked out to an estimated treatment difference of 13.7 percentage points versus placebo. NIH’s summary framed that more concretely: about 12 fewer heavy drinking days in the past 30 days, versus about eight fewer in the placebo group. ### Was it just self-reporting? Not entirely — and that matters in alcohol trials. The researchers tracked self-reported drinking, but they also looked at blood-based alcohol biomarkers, which moved in the same direction. That does not make the study perfect, but it does make the signal harder to dismiss as wishful reporting. Why would a weight-loss drug affect drinking? Basically, GLP-1 drugs do more than slow digestion and reduce appetite. Researchers have been increasingly interested in their effects on reward circuits, craving, and cue-driven behavior. The idea is that a drug that lowers the “pull” of food might also lower the pull of alcohol for some patients. This trial does not prove the full mechanism, but it strengthens the case that the effect is real. ### Did anything else improve? Yes. The semaglutide group also showed reductions in alcohol craving, total alcohol consumption, and drinks per drinking day in coverage of the trial, plus the expected improvements in weight and blood pressure. There were gastrointestinal side effects, but they were described as mild and transient. The catch is the study population was specific: adults with both alcohol use disorder and obesity, treated at a single center, and mostly White. That means you should not automatically assume the same effect size in people without obesity, in broader clinical settings, or across other substance-use disorders. ### Why are people so excited anyway? Because the bar in this field is not “interesting biology.” The bar is “does it help real patients drink less?” On that question, semaglutide just cleared an important hurdle. NIH also highlighted a number needed to treat of 4.3 in this study, which compares well with existing alcohol-use medications that often have estimates of 7 or higher. ### So what is the bottom line? This is the first randomized evidence that a GLP-1 receptor agonist can reduce heavy drinking in people with alcohol use disorder and obesity. It is still early, and bigger trials need to show who benefits most. But the story changed last week — semaglutide is no longer just a speculative addiction drug. It is now a serious candidate.
